Skip to content
  • Events
  • LN
  • Join PMC
  • SR
  • Events
  • LN
  • Join PMC
  • SR
  • About
    • Leadership
    • Board of Directors
  • Personalized Medicine 101
  • Policy
    • Public Policy
    • Science Policy
    • Congressional Caucus
  • Research
    • PGx Drug-Gene Associations
  • Membership
    • Committees & Working Groups
    • Current Members
    • Friends of PMC
    • Member Login
  • News and Resources
    • Leadership Blog
    • Press Releases
    • Multimedia Resources
  • Events
  • Join PMC
Menu
  • About
    • Leadership
    • Board of Directors
  • Personalized Medicine 101
  • Policy
    • Public Policy
    • Science Policy
    • Congressional Caucus
  • Research
    • PGx Drug-Gene Associations
  • Membership
    • Committees & Working Groups
    • Current Members
    • Friends of PMC
    • Member Login
  • News and Resources
    • Leadership Blog
    • Press Releases
    • Multimedia Resources
  • Events
  • Join PMC

Policy Category: Regulation

PMC advises regulators on public policies that can help facilitate the efficient review of personalized medicine products. For example, PMC explained how certain enhancements to the U.S. Food and Drug Administration (FDA)’s drug and medical device user fee programs could help advance personalized medicine while participating in a series of public workshops FDA convened to discuss the user fee programs in 2020, 2021, and 2022. Many of PMC’s recommended changes went into effect with the passage of new user fee reauthorization laws in 2022.

FDA Guidance on Pharmacogenomic Data Submissions

U.S. House of Representatives Ways and Means Health Subcommittee Hearing on Policies That Inhibit Innovation and Patient Access

Reauthorization of FDA’s Prescription Drug and Medical Device User Fee Programs

Support for the Nomination and Confirmation of FDA Commissioners

FDA’s Publication of a List of Patient Preference-Sensitive Priorities

Framework for Oversight of Diagnostic Testing in the United States

FDA’s Oversight of Development and Labeling for In Vitro Companion Diagnostic Devices in Oncology

FDA’s Oversight of Gene Therapies

European Medicines Agency’s 2017 Concept Paper on Predictive Biomarker-Based Assay Development

FDA’s Oversight of Diagnostic-Drug Co-Development

← older

Blog
Read the latest

Resources
Download publications

Personalized Medicine Coalition
1710 Rhode Island Ave. NW
Suite 700
Washington, DC 20036

202-589-1770
pmc@personalizedmedicinecoalition.org

  • Join PMC
  • SR
  • LN
  • Member Portal
  • Join PMC
  • SR
  • LN
  • Member Portal

© 2023 Personalized Medicine Coalition. All rights reserved. | Privacy Policy